Cite
HARVARD Citation
Matsutani, T. et al. (n.d.). FRI0206 Abatacept (CTLA4-IG) suppresses T cell activation and reduces TH17 cells as well as plasma IL-6 in patients with rheumatoid arthritis. Annals of the rheumatic diseases. p. 383. [Online].